MyCural Therapeutics
MyCural Therapeutics is developing a cancer therapy for patients with aggressive high-risk tumors. The MYC oncoprotein is the main driver of more than 50% of all cancers, which leads to aggressive tumors, resistance to cancer treatment and poor prognosis. There are currently no specific drugs against MYC. Mycural Therapeutics has patented effective, selective small molecule MYC inhibitors that can be developed into drugs and cancer therapy for patients with intractable MYC-driven tumors. This could revolutionize the treatment of patients with currently non curable tumors in late stages.
MyCural Therapeutics
MyCural Therapeutics utvecklar en cancerterapi för patienter med aggressiva högrisk-tumörer. Mer än hälften av alla tumörer har felaktig reglering av cancergenen MYC vilket leder till aggressiva tumörer, resistens mot cancerbehandling och dålig prognos. Det finns idag inga specifika läkemedel mot MYC. Mycural Therapeutics har patenterat effektiva, selektiva småmolekylära MYC-hämmare som kan utvecklas till läkemedel och cancerterapi för patienter med svårbehandlade MYC-drivna tumörer. Detta kan revolutionera behandlingen av patienter med idag obotliga tumörer i sena stadier.